Full index of posts »
Latest Followers
StockTalks
-
The most biased bearish $NOK article ever written at MF, http://bit.ly/VysXiU , have a laugh Dec 4, 2012
-
Do yourself a favor and don't try to hedge the macro with AAPL, as the Topeka analyst on CNBC recommends http://yhoo.it/URtpwl Nov 19, 2012
-
AMRN Talks with BP confirmed, NCE unclarity hindering progress. FDA has communicated to have drafted a response to AMRN. Nov 8, 2012
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.
View Juuso E's Instablogs on:
ONXX Did Not Suffer A Trial Failure
It's outrageous that the more or less popular sites such as Wall Street Cheat Sheet do not excercise more care when choosing a title for their articles -
Title: "Cancer drug Nexavar from Bayer and Onyx fails in a late-stage combo trial"
The reality of the situation, quoted from the Article:
"Nexavar treatment for liver cancer, which is made jointly by Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) and Bayer A.G.(BAYZF.PK), was used in combination with Tarceva, but the pairing failed to improve survival rates compared with Nexavar on its own in a Phase III trial."
Nexavar + Tarceva = Nexavar, how'd Nexavar fail?
Disclosure: I am long ONXX.